Literature DB >> 33529230

High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector.

Maria V Sinegubova1, Nadezhda A Orlova1, Sergey V Kovnir1, Lutsia K Dayanova2, Ivan I Vorobiev1,2.   

Abstract

The spike (S) protein is one of the three proteins forming the coronaviruses' viral envelope. The S protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has a spatial structure similar to the S proteins of other mammalian coronaviruses, except for a unique receptor-binding domain (RBD), which is a significant inducer of host immune response. Recombinant SARS-CoV-2 RBD is widely used as a highly specific minimal antigen for serological tests. Correct exposure of antigenic determinants has a significant impact on the accuracy of such tests-the antigen has to be correctly folded, contain no potentially antigenic non-vertebrate glycans, and, preferably, should have a glycosylation pattern similar to the native S protein. Based on the previously developed p1.1 vector, containing the regulatory sequences of the Eukaryotic translation elongation factor 1 alpha gene (EEF1A1) from Chinese hamster, we created two expression constructs encoding SARS-CoV-2 RBD with C-terminal c-myc and polyhistidine tags. RBDv1 contained a native viral signal peptide, RBDv2 -human tPA signal peptide. We transfected a CHO DG44 cell line, selected stably transfected cells, and performed a few rounds of methotrexate-driven amplification of the genetic cassette in the genome. For the RBDv2 variant, a high-yield clonal producer cell line was obtained. We developed a simple purification scheme that consistently yielded up to 30 mg of RBD protein per liter of the simple shake flask cell culture. Purified proteins were analyzed by polyacrylamide gel electrophoresis in reducing and non-reducing conditions and gel filtration; for RBDv2 protein, the monomeric form content exceeded 90% for several series. Deglycosylation with PNGase F and mass spectrometry confirmed the presence of N-glycosylation. The antigen produced by the described technique is suitable for serological tests and subunit vaccine studies.

Entities:  

Year:  2021        PMID: 33529230     DOI: 10.1371/journal.pone.0242890

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  11 in total

1.  Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid.

Authors:  Yong Jiang; Qian Yan; Cheng-Xin Liu; Chen-Wen Peng; Wen-Jiang Zheng; Hong-Fa Zhuang; Hui-Ting Huang; Qiong Liu; Hui-Li Liao; Shao-Feng Zhan; Xiao-Hong Liu; Xiu-Fang Huang
Journal:  Comput Biol Med       Date:  2022-05-19       Impact factor: 6.698

2.  Antigenic properties of the SARS-CoV-2 nucleoprotein are altered by the RNA admixture.

Authors:  Denis E Kolesov; Maria V Sinegubova; Irina V Safenkova; Ivan I Vorobiev; Nadezhda A Orlova
Journal:  PeerJ       Date:  2022-01-07       Impact factor: 2.984

3.  Glycosylation of Receptor Binding Domain of SARS-CoV-2 S-Protein Influences on Binding to Immobilized DNA Aptamers.

Authors:  Fedor Grabovenko; Liudmila Nikiforova; Bogdan Yanenko; Andrey Ulitin; Eugene Loktyushov; Timofei Zatsepin; Elena Zavyalova; Maria Zvereva
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

4.  Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD.

Authors:  Denis E Kolesov; Maria V Sinegubova; Lutsia K Dayanova; Inna V Dolzhikova; Ivan I Vorobiev; Nadezhda A Orlova
Journal:  Diagnostics (Basel)       Date:  2022-02-03

5.  Phosphate-regulated expression of the SARS-CoV-2 receptor-binding domain in the diatom Phaeodactylum tricornutum for pandemic diagnostics.

Authors:  Samuel S Slattery; Daniel J Giguere; Emily E Stuckless; Arina Shrestha; Lee-Ann K Briere; Alexa Galbraith; Stephen Reaume; Xenia Boyko; Henry H Say; Tyler S Browne; Mallory I Frederick; Jeremy T Lant; Ilka U Heinemann; Patrick O'Donoghue; Liann Dsouza; Steven Martin; Peter Howard; Christopher Jedeszko; Kinza Ali; Garth Styba; Martin Flatley; Bogumil J Karas; Gregory B Gloor; David R Edgell
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

6.  A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice.

Authors:  Liqin Liu; Tingting Chen; Lizhi Zhou; Jie Sun; Yuqian Li; Meifeng Nie; Hualong Xiong; Yuhe Zhu; Wenhui Xue; Yangtao Wu; Tingting Li; Tianying Zhang; Zhibo Kong; Hai Yu; Jun Zhang; Ying Gu; Qingbing Zheng; Qinjian Zhao; Ningshao Xia; Shaowei Li
Journal:  Front Microbiol       Date:  2022-04-26       Impact factor: 6.064

7.  Designed SARS-CoV-2 receptor binding domain variants form stable monomers.

Authors:  Miriam Klausberger; Nikolaus F Kienzl; Gerhard Stadlmayr; Clemens Grünwald-Gruber; Elisabeth Laurent; Katharina Stadlbauer; Florian Stracke; Klemens Vierlinger; Manuela Hofner; Gabriele Manhart; Wilhelm Gerner; Florian Grebien; Andreas Weinhäusel; Lukas Mach; Gordana Wozniak-Knopp
Journal:  Biotechnol J       Date:  2022-02-03       Impact factor: 5.726

8.  Silent Antibodies Start Talking: Enhanced Lateral Flow Serodiagnosis with Two-Stage Incorporation of Labels into Immune Complexes.

Authors:  Dmitriy V Sotnikov; Nadezhda A Byzova; Anatoly V Zherdev; Youchun Xu; Boris B Dzantiev
Journal:  Biosensors (Basel)       Date:  2022-06-21

9.  Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay.

Authors:  Termsak Tantiwiwat; Apisitt Thaiprayoon; Ake-Kavitch Siriatcharanon; Chakrit Tachaapaikoon; Nongluk Plongthongkum; Dujduan Waraho-Zhmayev
Journal:  Mol Biotechnol       Date:  2022-09-14       Impact factor: 2.860

10.  Epitope-Specific Response of Human Milk Immunoglobulins in COVID-19 Recovered Women.

Authors:  Tatyana V Bobik; Nikita N Kostin; George A Skryabin; Polina N Tsabai; Maria A Simonova; Vera D Knorre; Yuliana A Mokrushina; Ivan V Smirnov; Julia A Kosolapova; Valentina V Vtorushina; Evgeniya V Inviyaeva; Evgeniya Polushkina; Ulyana L Petrova; Anna V Levadnaya; Lyubov V Krechetova; Roman G Shmakov; Gennadiy T Sukhikh; Alexander G Gabibov
Journal:  Pathogens       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.